Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Ten-Year Treatment Outcomes of Radical Prostatectomy Vs External Beam Radiation Therapy Vs Brachytherapy for 1503 Patients With Intermediate-risk Prostate Cancer.

Goy BW, Burchette R, Soper MS, Chang T, Cosmatos HA.

Urology. 2019 Nov 5. pii: S0090-4295(19)30943-4. doi: 10.1016/j.urology.2019.09.040. [Epub ahead of print]

PMID:
31704459
2.

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.

Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR.

JAMA. 2018 Mar 6;319(9):896-905. doi: 10.1001/jama.2018.0587.

3.

Treatment results of brachytherapy vs. external beam radiation therapy for intermediate-risk prostate cancer with 10-year followup.

Goy BW, Soper MS, Chang T, Slezak JM, Cosmatos HA, Tome M.

Brachytherapy. 2016 Nov - Dec;15(6):687-694. doi: 10.1016/j.brachy.2016.06.015. Epub 2016 Sep 3.

PMID:
27600607
4.

Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.

Smith GD, Pickles T, Crook J, Martin AG, Vigneault E, Cury FL, Morris J, Catton C, Lukka H, Warner A, Yang Y, Rodrigues G.

Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):505-16. doi: 10.1016/j.ijrobp.2014.11.018. Epub 2015 Jan 13.

PMID:
25596107
5.

Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.

Boehm K, Schiffmann J, Tian Z, Lesmana H, Larcher A, Mandel P, Karakiewicz PI, Graefen M, Schwarz R, Krüll A, Tilki D.

Urol Oncol. 2016 Mar;34(3):119.e11-8. doi: 10.1016/j.urolonc.2015.09.012. Epub 2015 Oct 23.

PMID:
26602027
6.

Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis.

Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G, Nickols NG, Aronson WJ, Sadeghi A, Kamrava M, Demanes DJ, Steinberg ML, Horwitz EM, Kupelian PA, King CR.

Eur Urol. 2017 May;71(5):766-773. doi: 10.1016/j.eururo.2016.06.046. Epub 2016 Jul 21.

PMID:
27452951
7.

External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.

Wang C, Kishan AU, Kamrava M, Steinberg ML, King CR.

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1045-1052. doi: 10.1016/j.ijrobp.2017.03.040. Epub 2017 Mar 31.

PMID:
28721887
8.

Survival after radiotherapy vs. radical prostatectomy for unfavorable intermediate-risk prostate cancer.

Sebastian NT, McElroy JP, Martin DD, Sundi D, Diaz DA.

Urol Oncol. 2019 Nov;37(11):813.e11-813.e19. doi: 10.1016/j.urolonc.2019.04.022. Epub 2019 May 18.

PMID:
31109836
9.
10.

Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA.

Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):25-33.

PMID:
14697417
11.

Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis.

Hayashi N, Osaka K, Muraoka K, Hasumi H, Makiyama K, Kondo K, Nakaigawa N, Yao M, Mukai Y, Sugiura M, Takano S, Ito E, Kaizu H, Koike I, Hata M, Taguri M, Miyoshi Y, Izumi K, Kawahara T, Uemura H.

World J Urol. 2019 Dec 24. doi: 10.1007/s00345-019-03056-3. [Epub ahead of print]

PMID:
31875247
12.

Survival Significance of Patients With Low Prostate-Specific Antigen and High-Grade Prostate Cancer After Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy.

Guo Y, Mao S, Zhang A, Zhang J, Wang L, Wang R, Zhang W, Zhang Z, Wu Y, Cao X, Yang B, Yao X.

Front Oncol. 2019 Jul 19;9:638. doi: 10.3389/fonc.2019.00638. eCollection 2019.

13.

Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study.

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):883-888. doi: 10.1016/j.ijrobp.2018.03.060. Epub 2018 Apr 5.

PMID:
29976500
15.

Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention.

Zelefsky MJ, Pei X, Teslova T, Kuk D, Magsanoc JM, Kollmeier M, Cox B, Zhang Z.

BJU Int. 2012 Dec;110(11):1696-701. doi: 10.1111/j.1464-410X.2012.11385.x. Epub 2012 Aug 13.

16.

A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer.

Ciezki JP, Weller M, Reddy CA, Kittel J, Singh H, Tendulkar R, Stephans KL, Ulchaker J, Angermeier K, Stephenson A, Campbell S, Haber GP, Klein EA.

Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):962-975. doi: 10.1016/j.ijrobp.2016.12.014. Epub 2016 Dec 18.

PMID:
28333019
17.

Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.

Wedde TB, Småstuen MC, Brabrand S, Fosså SD, Kaasa S, Tafjord G, Russnes KM, Hellebust TP, Lilleby W.

Radiother Oncol. 2019 Mar;132:211-217. doi: 10.1016/j.radonc.2018.10.013. Epub 2018 Oct 30.

PMID:
30389241
18.

Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity.

Nepple KG, Stephenson AJ, Kallogjeri D, Michalski J, Grubb RL 3rd, Strope SA, Haslag-Minoff J, Piccirillo JF, Ciezki JP, Klein EA, Reddy CA, Yu C, Kattan MW, Kibel AS.

Eur Urol. 2013 Sep;64(3):372-8. doi: 10.1016/j.eururo.2013.03.005. Epub 2013 Mar 13.

19.

Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer.

King MT, Chen MH, Moran BJ, Braccioforte MH, Buzurovic I, Muralidhar V, Yang DD, Mouw KW, Devlin PM, D'Amico AV, Nguyen PL, Orio PF 3rd.

Urol Oncol. 2018 Apr;36(4):157.e15-157.e20. doi: 10.1016/j.urolonc.2017.11.022. Epub 2017 Dec 21.

PMID:
29276060
20.

Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.

Westover K, Chen MH, Moul J, Robertson C, Polascik T, Dosoretz D, Katin M, Salenius S, D'Amico AV.

BJU Int. 2012 Oct;110(8):1116-21. doi: 10.1111/j.1464-410X.2012.11012.x. Epub 2012 Apr 30.

Supplemental Content

Support Center